Trial Profile

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CHS 114 (Primary) ; Toripalimab (Primary)
Indications Carcinoma; Head and neck cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man

Most Recent Events

07 Nov 2025 According to a Coherus BioSciences media release, interim results from the trial were presented at at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland.
07 Nov 2025 Interim Results presented in the Coherus BioSciencesMedia Release
30 Apr 2025 Results (As of October 20, 2024, n=30) assessing safety and efficacy of CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com